title: Flare-up rates with bimatoprost therapy in uveitic glaucoma.
abstract: OBJECTIVE
  To evaluate the rate of flares in patients with uveitic glaucoma treated with topical bimatoprost and to assess its effect on intraocular pressure (IOP) in this subset of patients.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  All patients seen at one subspecialty uveitis practice with history of uveitic glaucoma treated with topical bimatoprost were identified and the data collected, which included onset, type, duration of uveitis, onset of secondary glaucoma, and previous therapies for glaucoma. The time of onset of bimatoprost therapy, the IOP, and flare-up rate before and after initiation of treatment with bimatoprost were recorded at one week and one, three, and six months of follow-up.
  
  
  RESULTS
  Of the 42 patients (59 eyes) identified, 12 patients had used other topical lipid agents, which were replaced by bimatoprost. Twenty-three patients had not used any lipid agents and bimatoprost was added to their existing antiglaucoma regimen. Seven patients were newly diagnosed with uveitic glaucoma and were commenced with topical bimatoprost. The rate of uveitis flares while on other antiglaucoma therapy was 52 per 100 person-years follow-up, while on bimatoprost therapy it was 32.4 per 100 person-years follow-up (P = .206). The mean IOP prior to bimatoprost therapy was 27 +/- 13.2 mm Hg and after initiation of topical bimatoprost was 15 +/- 5.5 mm Hg at the end of six months (P = .0008).
  
  
  CONCLUSIONS
  These data suggest that bimatoprost is an effective IOP-lowering agent in patients with uveitic glaucoma in whom the uveitis is controlled on immunomodulatory therapy, and it does not increase the rate of flares of uveitis in these patients.
authors.affiliation: Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts 02142, USA.
authors.forename: Egidio
authors.initials: E
authors.lastname: Fortuna
authors.forename: Rene A
authors.initials: RA
authors.lastname: Cervantes-Castañeda
authors.forename: Rene A
authors.initials: RA
authors.lastname: Castañeda-Cervantes
authors.forename: Pooja
authors.initials: P
authors.lastname: Bhat
authors.forename: Priyanka
authors.initials: P
authors.lastname: Doctor
authors.forename: C Stephen
authors.initials: CS
authors.lastname: Foster
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000627:therapeutic use*; D000867:Anterior Chamber / Q000473:pathology; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000069580:Bimatoprost; D002648:Child; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005901:Glaucoma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D014065:Tonometry, Ocular; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D055815:Young Adult
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D007155:Immunologic Factors; D003008:Cloprostenol; D000069580:Bimatoprost